Atossa Therapeutics Reports Promising (Z)-Endoxifen Trial Results for Breast Cancer Treatment and Risk Reduction

Reuters12-15
Atossa <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Promising <a href="https://laohu8.com/S/Z">$(Z)$</a>-Endoxifen Trial Results for Breast <a href="https://laohu8.com/S/CTHZ">Cancer Treatment</a> and Risk Reduction

Atossa Therapeutics Inc., a clinical-stage biopharmaceutical company, presented four clinical trial updates related to its investigational drug (Z)-endoxifen at the 2025 San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025. The presentations included initial results from the RECAST DCIS multicenter platform trial, which is evaluating active surveillance and novel endocrine therapy agents for the management of ductal carcinoma in situ (DCIS). Early pharmacodynamic data indicated that 86% of patients achieved a Week 4 Ki-67 ≤10%, supporting the selection of 40 mg (Z)-endoxifen with ovarian function suppression for Phase II studies. The trial is also assessing whether short-term endocrine therapy combined with MRI response assessment can identify DCIS patients suitable for long-term active surveillance and potentially avoid surgery. The findings showed promising antiproliferative efficacy, good tolerability, and steady enrollment, with many patients choosing to continue active surveillance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF45964) on December 15, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment